If you’re looking for stock ideas, Cramer says thanks to good ol’ American ingenuity, this sector is bursting with them.» Read More
NEW YORK— Drugmakers Regeneron Pharmaceuticals and Sanofi said Tuesday that an experimental drug reduced symptoms of chronic sinusitis in a clinical trial. Shares of Regeneron Pharmaceuticals Inc. rose $5.26 to $306.22 in morning trading. Sanofi stock added $1 to $56.71.
Sept 26- Alimera Sciences Inc and pSivida Corp said the U.S. Food and Drug Administration approved their vision-loss treatment Iluvien, following three rejections. Iluvien, which will compete with Regeneron Pharmaceuticals Inc's Eylea and Roche AG's Lucentis, is expected to be available in the United States in early 2015..
*Roche, Novartis say Lucentis is most appropriate drug. Avastin is not licensed for wAMD but it works in a similar way to authorized treatments for the condition- Lucentis, which is marketed by Novartis and Roche, and Eylea, from Bayer and Regeneron Pharmaceuticals.
Like to game Fantasy Football? Then, you may love picking stocks.
The dynamics in the market are changing. And Cramer says investors need to change, accordingly.
That clinical trials for a cholesterol-lowering drug exceed expectations will boost the developer's stock, says CNBC's Jim Cramer.
Some of the names on the move ahead of the open.
*Novartis's LCZ696 and PCSK9 drugs could treat millions. Hopes have spiked for a heart failure drug from Novartis and an innovative class of injectable anti-cholesterol agents known as PCSK9 inhibitors after the release of data at the ESC's annual meeting indicated that they can save more lives than standard therapies.
*Sanofi, Regeneron vying with drugs from Amgen and Pfizer. BARCELONA, Aug 31- An experimental cholesterol-lowering drug from Sanofi and Regeneron Pharmaceuticals roughly halved the number of heart attacks and strokes in a clinical trial, researchers reported on Sunday.
*Best Buy tumbles after results, DSW higher. *Digital Ally gains again, has tripled this month. "People aren't going to do anything too aggressive until there's some kind of catalyst, either positive or negative, and we may end up consolidating around 2,000 for a while," said Michael O'Rourke, chief market strategist at JonesTrading in Greenwich, Connecticut.
Biotechs rallied after Roche Holding AG agreed to buy InterMune Inc for $8.3 billion in cash, the latest vote of confidence in a sector that many, including Federal Reserve Chair Janet Yellen, are worried is overvalued. InterMune jumped 36 percent to $73.00, with the Nasdaq Biotech index up 2.4 percent.
Cramer often look inside the market for insights on broad sentiment. And certain things happened on Wednesday that suggest trouble.
Some of Tuesday's midday movers:
Aug 5- Regeneron Pharmaceuticals Inc on Tuesday reported higher-than-expected quarterly revenue and earnings on surging demand for its Eylea treatment for macular degeneration, and stuck to its full-year sales forecast for the drug.
Cramer likes to review the S&P 500’s Daily Action Charts in an effort to find stocks that could work higher.
Some of Wednesday's midday movers:
*Twitter rallies after blockbuster results. NEW YORK, July 30- U.S. stocks were flat on Wednesday, paring earlier gains as a strong read on second-quarter economic growth sparked concerns the Federal Reserve may adjust its stimulus earlier than expected.
*Twitter rallies after blockbuster results. *Biotechs rally on Amgen results, Regeneron trial data. Twitter Inc surged on heavy volume, jumping 25 percent to $48.25 in its biggest one-day advance ever after reporting that monthly active users had risen a better-than-expected 24 percent in the second quarter.
CNBC's Jim Cramer on Wednesday identified two biotechnology stocks that he thinks could climb.
Regeneron Pharmaceuticals said the U.S. Food and Drug Administration has approved the use of Eylea for the treatment of diabetic macular edema.